Company Filing History:
Years Active: 2024
Title: Sandesh Seth: Innovator in Gene-Edited Cell-Based Therapies
Introduction
Sandesh Seth is a notable inventor based in New York, NY (US). He has made significant contributions to the field of gene-edited cell therapies. His innovative approach focuses on improving treatment methods for non-cancerous disorders.
Latest Patents
Seth holds a patent for "Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies." This invention provides a method for depleting a subject's hematopoietic stem cells by administering an effective amount of a radiolabeled anti-CD45 antibody, such as I-BC8 or Ac-BC8. Additionally, the patent outlines a method for treating subjects afflicted with non-cancerous disorders through genetically edited cell therapy. This involves administering a radiolabeled anti-CD45 antibody to deplete hematopoietic stem cells, followed by therapy to address the subject's disorder. The invention also includes articles of manufacture for performing these methods.
Career Highlights
Seth is currently associated with Actinium Pharmaceuticals, Limited, where he continues to advance his research and innovations. His work is pivotal in the development of therapies that leverage gene editing for improved patient outcomes.
Collaborations
Some of his notable coworkers include Mark Berger and Keisha Thomas, who contribute to the collaborative efforts at Actinium Pharmaceuticals.
Conclusion
Sandesh Seth's contributions to gene-edited cell therapies exemplify the innovative spirit in the medical field. His patent reflects a significant advancement in treatment methodologies, showcasing the potential of targeted therapies in addressing complex health issues.